Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04491682
Other study ID # 53211029-01
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date September 1, 2020
Est. completion date June 20, 2022

Study information

Verified date January 2024
Source Fudan University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To see if megestrol acetate plus rosuvastatin will be superior to reversing the endometrial lesion to a normal endometrium than megestrol acetate alone in patients with atypical endometrial hyperplasia (AEH). Considering the large sample size in RCT, we used Simon two-stage design.


Description:

After diagnosed of AEH by hysteroscopy, patients will be enrolled. Age, height, weight, waist circumstances, blood pressure, basic history of infertility and blood pressure will be collected. Blood tests, including fasting blood glucose (FBG), fasting insulin (FINS), OGTT 2h blood glucose and insulin, blood lipids, SHBG, sex hormone levels, anti-müllerian hormone(AMH), creatine kinase(CK) and renal/liver function tests will be performed before treatment to evacuate their basic conditions. Each subject will receive body fat testing by Inbody 520. Patients are randomized to 1 of 2 treatment groups. Patients will receive MA 160 mg plus rosuvastatin 10mg by mouth daily for at least 6 months. Then hysteroscopy will be used to evaluate the endometrial condition every 3 months, and intra-operative findings will be recorded. Complete response (CR) is defined as the reversion of endometrial atypical hyperplasia to proliferative or secretory endometrium; partial response (PR) is defined as regression to simple or complex hyperplasia without atypic; stable disease (SD) is defined as the persistence of the disease; and progressive disease (PD) is defined as the appearance of endometrial cancer in patients. Continuous therapies will be needed in PR or NR. Patients with PD will be recommended for hysterectomy. Two months of maintenance treatment will be recommended for patients with CR, and participants will be followed up for 2 years.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date June 20, 2022
Est. primary completion date June 20, 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Have a confirmed pathological diagnosis based upon hysteroscopy - Have a desire for remaining reproductive function or uterus - Good compliance with adjunctive treatment and follow-up - Abnormal blood lipid. At least meet one of the following five items: 1. Total cholesterol (TC) = 5.2mmol/L (200mg/dL) 2. Low-density lipoprotein cholesterol (LDL-C) = 3.4mmol/L (130mg/dL) 3. Fasting triglycerides (TG) = 1.7mmol/L (150mg/dL) 4. High-density lipoprotein cholesterol (HDL-C) < 1.03mmol/L (40mg/dL) 5. Apo-lipoprotein-A (Apo-A) < 1.0g/L Exclusion Criteria: - Acute liver disease or liver tumor (benign or malignant) or renal dysfunction - Pregnancy or potential pregnancy - Under treatment of high-dose progestin therapy more than 1 months in recent 6 months - Confirmed diagnosis of any cancer in reproductive system - Acute severe disease such as stroke or heart infarction or a history of thrombosis disease - Hypersensitivity or contradiction for using MA or statins - Already diagnosed with hyperlipidemia and using lipid-lowering drugs - With other factors of reproductive dysfunction; - Strong request for uterine removal or other conservative treatment - Smoker (>15 cigarettes a day) - Drinker (>20 grams a day)

Study Design


Intervention

Drug:
Megestrol Acetate
At a dosage of 160 mg/day
Rosuvastatin
At a dosage of 10 mg/day

Locations

Country Name City State
China Obstetrics and Gynecology Hospital, Fudan University Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pathological response rate From date of randomization or initial therapy until the date of CR or date of hysterectomy, whichever come first, assessed up to 16 weeks. 12 to 16 weeks
Secondary Pathological response rate From date of randomization or initial therapy until the date of CR or date of hysterectomy, whichever come first, assessed up to 32 weeks. 28 to 32 weeks
Secondary Pathological response duration Pathological response duration Up to 2 years
Secondary Pathological response rate classified by different blood lipid level Pathological response rate classified by different blood lipid level Up to 32 weeks
Secondary Toxicity evaluation Toxicity evaluation according to CTCAE 5.0 version. Up to 32 weeks
Secondary Relapse rate up to 2 years after the therapy for each patient
Secondary Pregnancy rate up to 2 years after the therapy for each patient
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02397083 - Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer Phase 2
Recruiting NCT05647109 - Patient-derived Tumor-like Cell Clusters Predict Progesterone Sensitivity in Patients With Early Endometrial Cancer
Active, not recruiting NCT00788671 - Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer Phase 2
Completed NCT04385667 - LVN- IUS Versus Oral Megesterol Acetate in Treatment of Atypical Endometrial Hyperplasia Phase 2/Phase 3
Withdrawn NCT01943058 - Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer Phase 2
Withdrawn NCT04683237 - Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia Phase 2/Phase 3
Completed NCT00483327 - Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate Phase 2
Recruiting NCT05316493 - Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia Phase 2/Phase 3
Completed NCT03241888 - Megestrol Acetate Plus LNG-IUS in Young Women With Endometrial Atypical Hyperplasia Phase 2/Phase 3
Recruiting NCT06390904 - GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients Phase 2/Phase 3
Recruiting NCT05316935 - GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients Phase 2/Phase 3
Recruiting NCT06379113 - GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients Phase 2/Phase 3
Recruiting NCT05172999 - Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia Phase 2/Phase 3
Recruiting NCT05675787 - Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia Phase 2
Active, not recruiting NCT03671811 - Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy Phase 2
Completed NCT00490087 - Resectoscopic Treatment of Atypical Endometrial Polyps in Fertile Women Phase 3
Terminated NCT04607252 - Metformin Plus Megestrol Acetate as a Fertility-sparing Treatment in Patients With Atypical Endometrial Hyperplasia Phase 2/Phase 3
Recruiting NCT05051722 - Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Active, not recruiting NCT00892866 - CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells N/A
Recruiting NCT03463252 - Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC Phase 2/Phase 3